Table 2:

Uptake and duration of antenatal maternal combination antiretroviral therapy, 2011–2016*

VariableDuration of therapy, wk; no. (%) of womenp value
≥ 4
n = 1315
< 4
n = 41
None
n = 51
Maternal risk category0.02
 Heterosexual899 (94.8)23 (2.4)26 (2.7)
 Injection drug use237 (89.8)7 (2.7)20 (7.6)
 Perinatal29 (90.6)2 (6.3)1 (3.1)
 Other37 (97.4)0 (0.0)1 (2.6)
Maternal race/ethnicity0.003
 Black698 (95.2)21 (2.9)14 (1.9)
 Indigenous277 (90.2)10 (3.3)20 (6.5)
 White230 (91.6)6 (2.4)15 (6.0)
 Other91 (95.8)3 (3.2)1 (1.1)
Infant province/territory of birth0.4
 Ontario474 (93.5)13 (2.6)20 (3.9)
 Quebec226 (93.8)6 (2.5)9 (3.7)
 Alberta209 (92.1)10 (4.4)8 (3.5)
 Saskatchewan159 (92.4)5 (2.9)8 (4.7)
 British Columbia/Yukon Territory142 (96.6)5 (3.4)0 (0.0)
 Manitoba100 (93.5)2 (1.9)5 (4.7)
 Atlantic provinces5 (83.3)0 (0.0)1 (16.7)
  • * Eleven women were excluded owing to unknown maternal treatment status; premature delivery occurred in 248 women (17.9%): 227 (17.3%) of those who received 4 weeks or more of antenatal combination antiretroviral therapy, 9 (22.0%) of those who received less than 4 weeks of such therapy and 12 (26.5%) for those who received no antenatal combination antiretroviral therapy (p = 0.2).

  • Unknown for 125 women; injection drug use was the predominant risk category in Saskatchewan (74.0%); it was also listed as a risk category for more than 10% of cases in British Columbia (39.0%), Manitoba (19.6%) and Alberta (16.7%). In Ontario and Quebec, it accounted for 6.7% and 5.0%, respectively, of cases with a risk category listed.

  • Unknown for 21 women; black ethnicity predominated in Quebec (73.9%), Ontario (67.1%) and Alberta (65.1%), whereas Indigenous ethnicity predominated in Saskatchewan (86.7%) and Manitoba (57.4%).